Treatment of Stage IV Rectal Cancer

Introduction to Treatment Strategies

The European Society for Medical Oncology recommends that patients with resectable oligometastatic disease should receive short-course radiotherapy (5×5 Gy) followed by combination chemotherapy and then surgical resection of both primary and metastatic sites, while those with unresectable metastases should start with systemic combination chemotherapy (FOLFOX or FOLFIRI with or without biologics) as the cornerstone of treatment 1, 2

For patients with resectable disease, the treatment sequence prioritizes cure and requires aggressive multimodality therapy, starting with short-course radiotherapy (5×5 Gy) to the primary tumor and adjacent nodes, followed immediately by combination chemotherapy starting 11-18 days later, with evaluation after 6-8 weeks, then performing surgery for metastases and primary tumor at approximately 3 months or when appropriate, and completing a total of 6 months of perioperative chemotherapy (pre- and postoperative combined) 1, 2
The American Society of Clinical Oncology suggests that short-course radiotherapy with combination chemotherapy provides higher dose intensity of systemic treatment compared to conventional chemoradiotherapy with fluoropyrimidine alone, which is a critical advantage in the treatment of stage IV rectal cancer 1, 2
Surgery for the primary can be safely delayed up to 5-6 months after radiotherapy when synchronous metastases are present, according to the National Comprehensive Cancer Network 1, 2

The European Society for Medical Oncology recommends that chemotherapy should be initiated early and consists of first-line fluoropyrimidines (5-FU/leucovorin or capecitabine) combined with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI), with or without monoclonal antibodies, and second-line chemotherapy should be considered for patients maintaining good performance status 1, 2, 3, 4
Bevacizumab (anti-VEGF) can be used regardless of KRAS mutation status, while cetuximab or panitumumab (EGFR inhibitors) are indicated only in wild-type KRAS tumors, as recommended by the American Society of Clinical Oncology 1, 2, 5

For patients with unresectable disease or poor performance status, palliative resection, fulguration, or radiotherapy followed by systemic therapy may be appropriate, and stenting procedures can be considered but may be difficult for lower tumors, according to the National Comprehensive Cancer Network 6, 7
Radiotherapy as a palliative procedure is reasonable for symptomatic control, as suggested by the European Society for Medical Oncology 1, 2

The multidisciplinary team must weigh age and comorbidities, patient preferences, and most importantly, a balanced evaluation of extent of primary versus metastatic disease to determine which constitutes the greatest threat, as well as performance status and ability to tolerate intensive therapy, according to the American Society of Clinical Oncology 1, 2, 6

The European Society for Medical Oncology recommends avoiding conventional long-course chemoradiotherapy (50 Gy with fluoropyrimidine) as upfront treatment in synchronous metastases, as this delays systemic therapy and reduces dose intensity, and ensuring KRAS mutation testing is performed before considering EGFR inhibitors, as these are ineffective in KRAS mutant tumors 1, 2
For bevacizumab use, maintaining at least a 6-week interval between the last dose and elective surgery due to wound healing concerns is recommended by the National Comprehensive Cancer Network 5

For patients with cT4b disease and metastases, the primary tumor is generally considered unresectable initially, and the approach depends on symptom burden, according to the National Comprehensive Cancer Network 8

The National Comprehensive Cancer Network recommends considering checkpoint inhibitors if microsatellite instability-high (MSI-H) in patients with stage IV rectal adenocarcinoma 8
For patients maintaining good performance status after first-line progression, switch to alternative chemotherapy backbone (FOLFOX to FOLFIRI or vice versa), as suggested by the European Society for Medical Oncology 9

Re-evaluate with imaging (CT or MRI) and tumor markers (CEA) after 2-3 cycles of chemotherapy, and assess both metastatic sites and primary tumor for response, according to the National Comprehensive Cancer Network 8